Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms
Sponsor: Liaquat University of Medical & Health Sciences
Summary
This prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of Escherichia coli 5C (Colipral®) in adult patients undergoing diagnostic colonoscopy. Participants will be randomized in a 1:1 ratio to receive either Colipral® or placebo for 14 days immediately after colonoscopy. The study aims to determine whether Colipral® reduces post-colonoscopy gastrointestinal symptoms compared with placebo, using validated symptom and stool assessment tools, patient-reported global improvement, and safety monitoring.
Official title: Evaluation of the Effectiveness of Escherichia Coli 5C in the Management of Post-Colonoscopy Symptoms: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2026-04-27
Completion Date
2026-10-30
Last Updated
2026-04-09
Healthy Volunteers
No
Interventions
Colipral®
Dietary supplement containing Escherichia coli 5C (Colipral®)
Placebo
Matching placebo
Locations (1)
University of Urbino Carlo Bo, Urbino, Italy
Urbino, Italy